Tuesday, September 29, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1tirzepatidemorphinedrug-interactioncase-report

Cureus case report ties tirzepatide start to opioid respiratory failure

A 53-year-old man stable on 180 mg/day sustained-action morphine for 13 years needed 12 mg intranasal naloxone six weeks after beginning tirzepatide.

MH
By Maren Holt · Senior Reporter, GLP-1
Aug 27 20:00 ETSource: Cureus

The wire

  1. 01Authors describe what they call the first reported case of life-threatening opioid toxicity after tirzepatide initiation at 2.5 mg weekly, escalated to 5 mg at week four, with acute kidney injury and ketonuria.
  2. 02Proposed mechanisms are delayed gastric emptying disrupting sustained-action morphine release plus dehydration-related impaired clearance of morphine-6-glucuronide, relevant wherever incretins are co-prescribed with chronic opioids.
  3. 03Single case report with confounding by other renally cleared CNS depressants; the authors call for formal pharmacokinetic study. Morphine was cut to 60 mg/day with reported equivalent pain control.

From the source

Opioid Toxicity Associated With Tirzepatide in a Patient on Chronic Oral Morphine

Cureus · 2026 Aug · Mataraarachchi NE, Dellinger OD 3rd, Babakhanians A et al.

Read at pubmed.ncbi.nlm.nih.gov
PeptiPrescribed peptides from $99/moSee all →